3.49
price down icon0.29%   -0.010
after-market After Hours: 3.49
loading
Arbutus Biopharma Corp stock is traded at $3.49, with a volume of 1.40M. It is down -0.29% in the last 24 hours and up +1.16% over the past month. Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
See More
Previous Close:
$3.50
Open:
$3.44
24h Volume:
1.40M
Relative Volume:
1.67
Market Cap:
$663.57M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-7.9318
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+2.95%
1M Performance:
+1.16%
6M Performance:
-9.35%
1Y Performance:
+35.27%
1-Day Range:
Value
$3.35
$3.54
1-Week Range:
Value
$3.20
$3.54
52-Week Range:
Value
$2.30
$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name
Name
Arbutus Biopharma Corp
Name
Phone
604-419-3200
Name
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Name
Employee
73
Name
Twitter
@arbutusbio
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
ABUS's Discussions on Twitter

Compare ABUS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ABUS
Arbutus Biopharma Corp
3.49 663.57M 12.99M -74.39M -78.92M -0.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-02-22 Upgrade Jefferies Hold → Buy
Feb-25-21 Initiated Jefferies Hold
Dec-17-20 Initiated H.C. Wainwright Buy
Jul-27-20 Resumed JMP Securities Mkt Outperform
Jul-24-20 Downgrade Robert W. Baird Outperform → Neutral
May-19-20 Upgrade Wedbush Neutral → Outperform
Mar-06-20 Upgrade Chardan Capital Markets Neutral → Buy
Feb-20-20 Initiated Robert W. Baird Outperform
Feb-05-20 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Oct-07-19 Reiterated B. Riley FBR Buy
Oct-04-19 Downgrade Chardan Capital Markets Buy → Neutral
Oct-16-18 Upgrade B. Riley FBR Neutral → Buy
Oct-15-18 Upgrade Wedbush Underperform → Neutral
Oct-12-18 Reiterated Chardan Capital Markets Buy
Jul-06-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Mar-19-18 Resumed Chardan Capital Markets Buy
Mar-19-18 Downgrade Wedbush Outperform → Neutral
Jan-05-18 Initiated B. Riley FBR, Inc. Buy
Apr-04-17 Upgrade Chardan Capital Markets Neutral → Buy
Feb-01-17 Reiterated Wedbush Outperform
Dec-13-16 Downgrade Chardan Capital Markets Buy → Neutral
Nov-30-16 Upgrade Chardan Capital Markets Neutral → Buy
View All

Arbutus Biopharma Corp Stock (ABUS) Latest News

pulisher
11:18 AM

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

11:18 AM
pulisher
10:24 AM

Warminster-Based Arbutus Biopharma Lays Off Over Half of Workforce, Exits Its Headquarters - BUCKSCO.Today

10:24 AM
pulisher
Mar 30, 2025

Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MSN

Mar 30, 2025
pulisher
Mar 30, 2025

Xponance Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Chardan Capital Reiterates “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Arbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong Earnings - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma earnings beat by $0.02, revenue fell short of estimates - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus stock gains after 57% workforce cuts (ABUS:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Was there any good news for Arbutus Biopharma Corp (ABUS) stock in the last session? - uspostnews.com

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma Announces 2024 Financial Results and Strategic Restructuring - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Charles Schwab Investment Management Inc. Acquires 9,955 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Mar 27, 2025
pulisher
Mar 20, 2025

Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery - MSN

Mar 20, 2025
pulisher
Mar 10, 2025

Reviewing Akari Therapeutics (NASDAQ:AKTX) and Arbutus Biopharma (NASDAQ:ABUS) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Are Arbutus Biopharma Corp’shares a good deal? - US Post News

Mar 07, 2025
pulisher
Mar 04, 2025

Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360

Mar 04, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan

Mar 03, 2025
pulisher
Feb 28, 2025

Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

StockNews.com Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Sell - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Brokers Issue Forecasts for ABUS FY2029 Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Brokers Set Expectations for ABUS FY2029 Earnings - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Arbutus Biopharma (NASDAQ:ABUS) Lowered to “Sell” Rating by StockNews.com - Defense World

Feb 26, 2025
pulisher
Feb 26, 2025

Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo

Feb 26, 2025
pulisher
Feb 25, 2025

Lindsay Androski named CEO of Arbutus - BioCentury

Feb 25, 2025
pulisher
Feb 25, 2025

Arbutus Biopharma appoints new CEO and reshapes board - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Hepatitis B Market to Reach New Heights in Growth by 2032, - openPR.com

Feb 25, 2025
pulisher
Feb 24, 2025

Arbutus Biopharma Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Feb 24, 2025
pulisher
Feb 20, 2025

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool

Feb 20, 2025
pulisher
Feb 20, 2025

Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN

Feb 20, 2025
pulisher
Feb 12, 2025

The Hidden Gem in Nasdaq’s Under $5 Club: Is Arbutus Biopharma the Next Big Thing? - Jomfruland.net

Feb 12, 2025
pulisher
Feb 12, 2025

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR

Feb 11, 2025
pulisher
Feb 11, 2025

10 Best Nasdaq Stocks Under $5 to Buy - Insider Monkey

Feb 11, 2025
pulisher
Feb 08, 2025

SG Americas Securities LLC Purchases 16,250 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Feb 08, 2025
pulisher
Feb 06, 2025

Arbutus Biopharma Corp (ABUS) Stock: A Look at the Monthly Trend - The News Heater

Feb 06, 2025
pulisher
Feb 05, 2025

Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Jefferies analysts upgrades a Buy rating for Arbutus Biopharma Corp (ABUS) - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Arbutus Biopharma Executives Sell Shares to Cover Tax Obligations - TradingView

Feb 05, 2025
pulisher
Feb 04, 2025

Arbutus Biopharma Corp (ABUS) expanding its growth trajectory ahead - SETE News

Feb 04, 2025
pulisher
Feb 04, 2025

Morgan Stanley Reduces Stake in Arbutus Biopharma Corp - GuruFocus

Feb 04, 2025
pulisher
Jan 30, 2025

JPMorgan Chase & Co. Increases Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 30, 2025
pulisher
Jan 27, 2025

Ballentine Partners LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 27, 2025

Arbutus Biopharma Corp Stock (ABUS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):